We're seeing AI evolve fast. It's no longer just about building a single, super-smart model. The real power, and the exciting frontier, lies in getting multiple specialized AI agents to work together.

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92% achieving MRD negativity. Safety profile is favorable, with no severe ...

CAMBRIDGE, Mass., Oct. 17, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I) ...

Researchers at Google and MIT have conducted a comprehensive analysis of agentic systems and the dynamics between the number of agents, coordination structure, model capability, and task properties.

AI agents are now getting proficient at handling everyday tasks like incident response, access provisioning and service requests. A single AI agent solving a narrow problem is, indeed, helpful. But as ...

What if you could delegate your most complex research tasks to an AI that not only understands the intricacies of your work but also evolves with every challenge it faces? Enter the Kimi K2 Agent ...

CAMBRIDGE, Mass., Nov. 7, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation & immunology (I&I), ...